247 related articles for article (PubMed ID: 32537883)
1. Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United States.
McGrath LJ; Spangler L; Curtis JR; Ehrenstein V; Sørensen HT; Saul B; Levintow SN; Reams D; Bradbury BD; Brookhart MA
Pharmacoepidemiol Drug Saf; 2020 Aug; 29(8):854-863. PubMed ID: 32537883
[TBL] [Abstract][Full Text] [Related]
2. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
3. Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States.
Kim M; Lin TC; Arora T; Zhao H; Balasubramanian A; Stad RK; O'Kelly J; Spangler L; Bradbury BD; Curtis JR
J Bone Miner Res; 2023 Jun; 38(6):829-840. PubMed ID: 37088886
[TBL] [Abstract][Full Text] [Related]
4. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates.
Miller PD; Pannacciulli N; Malouf-Sierra J; Singer A; Czerwiński E; Bone HG; Wang C; Huang S; Chines A; Lems W; Brown JP
Osteoporos Int; 2020 Jan; 31(1):181-191. PubMed ID: 31776637
[TBL] [Abstract][Full Text] [Related]
6. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
Higuchi T; Soga Y; Muro M; Kajizono M; Kitamura Y; Sendo T; Sasaki A
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jun; 125(6):547-551. PubMed ID: 29574058
[TBL] [Abstract][Full Text] [Related]
7. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Stopeck AT; Fizazi K; Body JJ; Brown JE; Carducci M; Diel I; Fujiwara Y; Martín M; Paterson A; Tonkin K; Shore N; Sieber P; Kueppers F; Karsh L; Yardley D; Wang H; Maniar T; Arellano J; Braun A
Support Care Cancer; 2016 Jan; 24(1):447-455. PubMed ID: 26335402
[TBL] [Abstract][Full Text] [Related]
8. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
Curtis JR; Xie F; Yun H; Saag KG; Chen L; Delzell E
Arthritis Rheumatol; 2015 Jun; 67(6):1456-64. PubMed ID: 25708920
[TBL] [Abstract][Full Text] [Related]
9. Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study.
Lee H; Jin Y; Roh M; Tsacogianis TN; Park S; Choi NK; Kim SC
Drugs Aging; 2020 Apr; 37(4):311-320. PubMed ID: 32026309
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.
Singer AJ; Liu J; Yan H; Stad RK; Gandra SR; Yehoshua A
Osteoporos Int; 2021 Dec; 32(12):2473-2484. PubMed ID: 34095966
[TBL] [Abstract][Full Text] [Related]
11. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
[TBL] [Abstract][Full Text] [Related]
12. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
13. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study.
Zullo AR; Lee Y; Lary C; Daiello LA; Kiel DP; Berry SD
Osteoporos Int; 2021 Mar; 32(3):565-573. PubMed ID: 33411003
[TBL] [Abstract][Full Text] [Related]
15. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
16. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
[TBL] [Abstract][Full Text] [Related]
17. Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.
Horne AM; Mihov B; Reid IR
Calcif Tissue Int; 2018 Jul; 103(1):55-61. PubMed ID: 29445836
[TBL] [Abstract][Full Text] [Related]
18. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
Shapiro CL; Moriarty JP; Dusetzina S; Himelstein AL; Foster JC; Grubbs SS; Novotny PJ; Borah BJ
J Clin Oncol; 2017 Dec; 35(35):3949-3955. PubMed ID: 29023215
[TBL] [Abstract][Full Text] [Related]
20. Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies.
Li W; Ning Z; Yang Z; Fan T; Yao M; Zhang W; Wang M; Wen A; Wang J
Arch Osteoporos; 2022 Jun; 17(1):84. PubMed ID: 35715524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
